Polar Capital reports 8.46% stake in Enliven Therapeutics

Enliven Therapeutics ownership filing: A group including Polar Capital Holdings Plc, Polar Capital LLP and Polar Capital Funds PLC - Biotechnology Fund reports beneficial ownership of 5,056,807 shares of Enliven Therapeutics common stock.

Rhea-AI Filing Summary

Enliven Therapeutics ownership filing: A group including Polar Capital Holdings Plc, Polar Capital LLP and Polar Capital Funds PLC - Biotechnology Fund reports beneficial ownership of 5,056,807 shares of Enliven Therapeutics common stock. The filing states this equals 8.46% of the class, based on 60,904,946 shares outstanding as of May 7, 2026.

The filing is a joint Schedule 13G/A amendment signed by Nicholas Farren as Chief Operating Officer for the reporting entities and affirms sole voting and sole dispositive power over the reported shares.

Insights

Institutional Ownership Analyst

Large passive stake disclosed by Polar Capital group.

The filing shows the Polar Capital entities jointly report holding 5,056,807 shares, equal to 8.46% of Enliven Therapeutics outstanding common stock as calculated from the issuer's Form 10-Q (60,904,946 shares as of May 7, 2026).

The disclosure lists sole voting and sole dispositive power for these shares. The filing is a standard beneficial-ownership disclosure under Schedule 13G/A and does not state trading intent or plans.

Key Figures

Beneficial ownership: 5,056,807 shares Percent of class: 8.46% Shares outstanding: 60,904,946 shares

3 metrics

Beneficial ownership 5,056,807 shares Amount beneficially owned reported on Schedule 13G/A

Percent of class 8.46% Percent of common stock based on issuer filing

Shares outstanding 60,904,946 shares Shares outstanding as reported in Issuer's Form 10-Q on <date>May 7, 2026</date>

Key Terms

Schedule 13G/A, Beneficially owned, Sole dispositive power

3 terms

Schedule 13G/A regulatory

"Joint Schedule 13G/A amendment filed by the reporting entities"

A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.

Beneficially owned financial

"Item 4. Ownership (a) Amount beneficially owned: 5,056,807"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

Sole dispositive power regulatory

"Item 4. (iii) Sole power to dispose or to direct the disposition of: 5,056,807"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stake does Polar Capital report in ENLVN?

Polar Capital and affiliated reporting entities state they beneficially own 5,056,807 shares, representing 8.46% of the common stock as disclosed in the filing.

How was the 8.46% ownership percentage calculated for ELVN?

The percentage is based on 60,904,946 shares outstanding as reported in Enliven Therapeutics' Form 10-Q on May 7, 2026, per the Schedule 13G/A text.

Who signed the Schedule 13G/A amendment for ENLVN?

The amendment is signed by Nicholas Farren in the capacity of Chief Operating Officer for Polar Capital Holdings Plc, Polar Capital LLP, and Polar Capital Funds PLC - Biotechnology Fund.

Does the filing disclose how Polar Capital acquired the shares of ENLVN?

The filing lists the beneficial ownership amount and powers but does not describe the acquisition method, timing, or whether shares were purchased or received by other means.

What voting and dispositive powers are reported for the ENLVN shares?

The filing reports sole voting power of 5,056,807 shares and sole dispositive power of 5,056,807 shares for the reporting entities.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/15/2026 - 05:26 PM EDT Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 2)

ENLIVEN THERAPEUTICS, INC.

(Name of Issuer)

Common Stock, $0.001 par value per share

(Title of Class of Securities)

29337E102

(CUSIP Number)

03/31/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 29337E102

1

Names of Reporting Persons

Polar Capital Holdings Plc

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED KINGDOM

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 5,056,807.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 5,056,807.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

5,056,807.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

8.46 %

12

Type of Reporting Person (See Instructions)

HC

SCHEDULE 13G

CUSIP Number(s): 29337E102

1

Names of Reporting Persons

Polar Capital LLP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED KINGDOM

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 5,056,807.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 5,056,807.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

5,056,807.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

8.46 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

CUSIP Number(s): 29337E102

1

Names of Reporting Persons

Polar Capital Funds PLC - Biotechnology Fund

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED KINGDOM

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 5,056,807.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 5,056,807.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

5,056,807.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

8.46 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

Item 1.
(a)	Name of issuer: ENLIVEN THERAPEUTICS, INC.
(b)	Address of issuer's principal executive offices: 6200 Lookout Road, Boulder, CO 80301
Item 2.
(a)	Name of person filing: Polar Capital Holdings Plc Polar Capital LLP Polar Capital Funds PLC - Biotechnology Fund
(b)	Address or principal business office or, if none, residence: 16 Palace Street London, SW1E 5JD George's Court, 54-62 Townsend Street Dublin 2, Ireland
(c)	Citizenship: United Kingdom
(d)	Title of class of securities: Common Stock, $0.001 par value per share
(e)	CUSIP No.: 29337E102
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 5,056,807
(b)	Percent of class: 8.46%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 5,056,807
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 5,056,807
	(iv) Shared power to dispose or to direct the disposition of: 0 Based on 60,904,946 shares outstanding as reported in the Issuer's Form 10-Q on May 7, 2026.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. Information for each Subsidiary is incorporated on the respective cover pages.
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Polar Capital Holdings Plc

Signature:	/s/ Nicholas Farren
Name/Title:	Nicholas Farren - Chief Operating Officer
Date:	05/15/2026

Polar Capital LLP

Signature:	/s/ Nicholas Farren
Name/Title:	Nicholas Farren - Chief Operating Officer
Date:	05/15/2026

Polar Capital Funds PLC - Biotechnology Fund

Signature:	/s/ Nicholas Farren
Name/Title:	Nicholas Farren - Chief Operating Officer
Date:	05/15/2026

Exhibit Information

Exhibit I JOINT FILING STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on SCHEDULE 13G, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on SCHEDULE 13G, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate. Polar Capital Holdings PLC By: /s/ Nicholas Farren Name: Nicholas Farren Title: Chief Operating Officer Polar Capital LLP By: /s/ Nicholas Farren Name: Nicholas Farren Title: Chief Operating Officer Polar Capital Funds PLC - Biotechnology Fund By: /s/ Nicholas Farren Name: Nicholas Farren Title: Chief Operating Officer